InsightRP2 Registry for RP2-associated Retinitis Pigmentosa
InsightRP2 Registry
Recruiting
Observational Study
RP2-associated Retinitis Pigmentosa
X-Linked Retinitis Pigmentosa (XLRP)
Retinitis Pigmentosa 2
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 200 (estimated)
- Sponsor
- University of Göttingen · Other
Who this trial is looking for
This trial is looking for individuals affected by RP2-associated retinitis pigmentosa. Participants will provide medical, genetic, and imaging data to help study this rare disease and research a potential gene therapy.
Are You a Good Fit for This Trial?
You may be able to join if
- I have a genetic diagnosis with a variant in RP2.
- I can give written consent to participate.
- I am of any age.
- I can understand English or German.
You may not be able to join if
- I have a different genetic diagnosis that is not related to RP2.
- I cannot give consent.
- I cannot navigate the registry documentation in English or German.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
InsightRP2 is a secure online patient registry specific to RP2-associated retinitis pigmentosa (RP). It is our goal to further the scientific understanding of this rare disease and to support research in to a gene therapy for RP2-associated RP.
We collect medical, genetic and imaging data from people affected by RP2-associated RP and will coduct a natural history study as well as image analysis s…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* A molecular genetic diagnosis involving a heterozygous or hemizygous variant in RP2 and a written informed consent to participate are required for access to the registry questionnaire. Patients of all ages meeting the above criteria will be allowed to participate. As documenta…
Contacts